PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab

To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and measured Lp(a) secretion from human hepatocyt...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Basic to translational science 2016-10, Vol.1 (6), p.419-427
Main Authors: Villard, Elise F, Thedrez, Aurélie, Blankenstein, Jorg, Croyal, Mikaël, Tran, Thi-Thu-Trang, Poirier, Bruno, Le Bail, Jean-Christophe, Illiano, Stéphane, Nobécourt, Estelle, Krempf, Michel, Blom, Dirk J, Marais, A David, Janiak, Philip, Muslin, Anthony J, Guillot, Etienne, Lambert, Gilles
Format: Article
Language:English
Subjects:
Food and Nutrition
Life Sciences
PRECLINICAL RESEARCH
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and measured Lp(a) secretion from human hepatocytes. They found that Lp(a) cellular uptake occurred in a low-density lipoprotein receptor-independent manner. Neither PCSK9 nor alirocumab altered Lp(a) internalization. By contrast, the secretion of apolipoprotein (a) from human hepatocytes was sharply increased by PCSK9, an effect that was reversed by alirocumab. They propose that PCSK9 does not significantly modulate Lp(a) catabolism, but rather enhances the secretion of Lp(a) from liver cells.
ISSN:2452-302X
2452-302X
DOI:10.1016/j.jacbts.2016.06.006